Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00815854 · ClinicalTrials.gov registry record · NA

Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects

A NA study of Schizophrenia, sponsored by University of Michigan.

Completed
Registry status
NA
Development phase
88
Enrollment target
1
Study location

NCT00815854 is a NA study of Schizophrenia that has completed, run by University of Michigan. The registered enrollment target is 88 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00815854, a NA study of Schizophrenia, has completed, sponsored by University of Michigan.

COMPLETED
Registry status
NA
Development phase
88 participants
Enrollment target
1
Study location

Study Summary

This study will examine possible causes of metabolic side effects in people taking atypical antipsychotic (AAP) medications.

Conditions Studied

Schizophrenia

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT Folic Acid

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2008-10
Est. Completion 2019-05
Phase NA

Sponsor

University of Michigan

1,327 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00815854

The ClinicalTrials.gov registry entry for NCT00815854 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (60% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00815854 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT00815854 about?

NCT00815854 is a clinical study titled "Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects". This study will examine possible causes of metabolic side effects in people taking atypical antipsychotic (AAP) medications.

What is the current status of trial NCT00815854?

This trial is currently completed. It is a NA study. The enrollment target is 88 participants. The study started on 2008-10. Estimated completion is 2019-05.

What conditions does trial NCT00815854 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT00815854?

The interventions under investigation include: Placebo (OTHER), Folic Acid (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00815854?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00815854 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.